Metabolism and Excretion of Illicit Drugs in Humans

Illicit Drugs in the Environment: Occurrence, Analysis, and Fate Using Mass Spectrometry

Volumn , Issue , 2011, Pages 29-52

  Melis, Manuela ^a   Castiglioni, Sara ^a   Zuccato, Ettore ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Illicit drug physiology illicit drug metabolism and excretion in humans; Metabolism, pharmacokinetic and excretion of main illicit drugs in humans; Opioids, and pain treatment drugs exerting pharmacological effects, on opioid receptor (MOP) group of G protein coupled receptors

Indexed keywords

EID: 84866873146     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118000816.ch2     Document Type: Chapter

References (53)

1. Baker, D., G. Pryce, G. Giovannoni, and A. J. Thompson. 2003. The therapeutic potential of cannabis. The Lancet 2:291-298.
2. Banta-Green, C. J., J. A. Field, A. C. Chiaia, D. L. Sudakin, L. Power, and L. de Montigny. 2009. The spatial epidemiology of cocaine, methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) use: A demonstration using a population measure of community drug load derived from municipal wastewater. Addiction 104:1874-1880.
3. Baselt, R. C. 2004. Disposition of Toxic Drugs and Chemicals in Man, seventh edition. Biomedical Publications, Foster City, CA, 2004.
4. Ben Amar, M. 2006. Cannabinoids in medicine: a review of their therapeutic potential. J. Ethopharmacol. 105:1-25.
5. Coller, J. K., L. L. Christrup and A. A. Somogyi. 2009. Role of active metabolites in the use of opioids. Europ. J. Clin. Pharmacol. 65:121-139.
6. Cone, E. J. 1998. Recent discoveries in pharmacokinetics of drugs of abuse. Toxicol. Lett. 102-103: 97-101.
7. Cone, E. J., and M. A. Huestis. 1993. Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage. Therap. Drug Monit. 15: 527-532.
8. Cone, E. J., and K. L. Preston. 2002. Toxicologic aspects of heroin substitution treatment. Therap. Drug Monit. 24:193-198.
9. Cruickshank, C. C., and K. R. Dyer. 2009. A review of the clinical pharmacology of methamphetamine. Addiction 104: 1085-1099.
10. D'Ascenzo, G., A. Di Corcia, A. Gentili, R. Mancini, R. Mastropasqua, M. Nazzari, and R. Samperi. 2003. Fate of natural estrogen conjugates in municipal sewage transport and treatment facilities. Sci. Total Environ. 302: 199-209.
11. Davis, J. M., I. J. Kopin, L. Lemberger, and J. Axelrod. 1971. Effects of urinary pH on amphetamine metabolism. Ann. N.Y. Acad. Sci. 179: 493-501.
12. De La Torre, R., J. Ortuño, M. L., Gonzàlez, M. Farrè, J. Camì, and J. Segua. 1995. Determination of cocaine and its metabolites in human urine by gas-chromatography/mass spectrometry after simultaneous use of cocaine and ethanol. J Pharmaceut. Biomed. Anal. 13: 305-312.
13. De La Torre, R., M. Farrè, M. Navarro, R. Pacifici, P. Zuccaro, and S. Pichini. 2004. Clinical pharmacokinetics of amphetamine and related substances. Monitoring in conventional and non-conventional matrices. Clin. Pharmaco. 43: 158-185.
14. Dean, R. A., E. T. Harper, N. Dumaual, D. A. Stoeckel, and W. F. Bosron. 1992. Effects of ethanol on cocaine metabolism: Formation of cocaethylene and norcocaethylene. Toxicol. Appl. Pharmacol. 117:1-8.
15. Dumas, E. O., and G. M. Pollack. 2008. Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. APPS J. 10: 537-551.
16. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2008. Insights 9. http://www.emcdda.europa.eu/publications/insights/wastewater. Accessed 15 July 2010.
17. Farooq, M. U., A. Bhatt, and M. B. Patel. 2009. Neurotoxic and cardiotoxic effects of cocaine and ethanol. J. Med. Toxicol. 5: 134-138.
18. Farrè, M., R. De La Torre, M. L. Gonzalez, M. T. Teràn, P. N. Roset, E. Menomo, and J. Camì. 1997. Cocaine and alcohol interactions in humans: Neuroendocrine effects and cocaethylene metabolism. J. Pharmacol. Exp. Therapeut. 283: 164-176.
19. Goldstein, R. A., C. DesLauries, and A. M. Burda. 2009. Cocaine: history, socialimplications, and toxicity-a review. Disease Month 55: 6-38.
20. Gonzalez,G., A. Oliveto, and T. R. Kosten. 2002. Treatment of heroin (diamorphine) addiction. Current approaches and future prospects. Drugs 62: 1331-1343.
21. Harris, D. S., E. T. Everhart, J. Mendelson, and R. T. Jones. 2003. The pharmacology of cocaethylene in humans following cocaine and ethanol administration. Drug Alcohol Dependence 72: 169-182.
22. Hart, C. L., E. W. Gunderson, A. Perez, M, G. Kirkpatrick, A. Thurmond, S. D. Comer, and R. W. Foltin. 2008. Acute physiological and behavioural effects of intranasal methamphetamine in humans. Neuropsycopharmacology 33:1847-1855.
23. Hawks, R. L., I. J. Kopin, R.W. Colburn, and N. B. Thoa. 1974. Norcocaine: A pharmacologically active metabolite of cocaine found in brain. Life Sci. 15:2189-2195.
24. Hegadoren, K. M., G. B. Baker, and M. Bourin. 1999. 3,4-Methylendioxy analogues of amphetamine: Defining the risks to humans. Neurosci. Biobehav. Rev. 23:539-553.
25. Holmquist, G. L. 2009. Opioid metabolism and effects of cytochrome P450. Pain Med. 10:S20-S29.
26. Huestis, M. A., and E. J. Cone. 1998. Urinary excretion half-life of 11-nor-9-carboxy-delta9-tetrahydrocannabinol in humans. Therapeut. Drug Monit. 20:570-576.
27. Huestis, M. A., and E. J. Cone. 2007. Methamphetamine disposition in oral fluid, plasma, and urine. Ann. N.Y. Acad. Sci. 1098:104-121.
28. Hutcheon, A. W., J. B. D. Palmer, M. Soukop, D. Cunnigham, C. McArdle, J. Welsh, F. Stuart, G. Sangster, S. Kaye, D. Charlton, and H. Cash. 1983. A randomised multicentre single blind comparison of a cannabinoid antiemetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemioterapy. Europ. J. Cancer Clin. Oncol. 19:1087-1090.
29. Jatlow, P., E. F. McCance, C.W. Bradberry, J. D. Elsworth, J. R. Taylor, and R. H. Roth. 1996. Alcohol plus cocaine: the whole is more than the sum of its parts. Therapeut. Drug Monit. 14:460-464.
30. Kim, I., J. M. Oyler, E. T. Moolchan, E. J. Cone, and M. A. Huestis. 2004. Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. Drug Monit. 26:664-672.
31. Kirkham, T. C. 2005. Endocannabinoids in the regulation of appetite and body weight. Behav. Pharmacol. 16:297-313.
32. Kraemer, T., and H. H. Maurer. 2002 Toxicokinetics of amphetamines: metabolism and toxicokinetic. Data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Therapeut. Drug Monit. 24:277-289.
33. Maurer, H. H., J. Bickeboeller-Friedrich, T. Kraemer, and F. T. Peters. 2000. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs (Ecstasy). Toxicol. Lett. 112-113:133-142.
34. Maurer, H. H., C. Sauer, and D. S. Theobald. 2006. Toxicokinetics of drugs of abuse: Current knowledge of isomers involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Therapeut. Drug Monit. 28:447-453.
35. Nicholson, B. 2003. Responsible prescribing of opioids for the management of chronic pain. Drugs 63:17-32.
36. Oyler, J. M., J. E. Cone, R. E. Joseph, Jr., E. T. Moolchan, and M. A. Huestis. 2002. Duration of detectable methamphetamine and amphetamine excretion in urine after controlled oral administration of methamphetamine to humans. Clin. Chem. 48:1703-1714.
37. Perfetti, X., B. Mathùna, N. Pizarro, E. Cuyàs, O. Khymenets, B., Almeida, M. Pellegrini, S. Pichini, S. S. Lau, T. J. Monks, M. Farrè, A. Pascual, J. Joglar, and R. De La Torre. 2009. Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion. Drug Metab. Disposition 37:1448-1455.
38. Peterson, K. L., K. L. Barry, and G. D. Christian. 1995. Detection of cocaine and its polar transformation products and metabolites in human urine. Forensic Sci. Int. 73:183-196.
39. Rook, E. J., A. D. R. Huitema,W. Van der Brink, J. M. Van Ree, and J. H. Beijnen. 2006. Population pharmacokinetics of heroin and its major metabolites. Clin. Pharmaco. 45:401-417.
40. Schepers, R. J. F., J. M. Oyler, R. E. Joseph, Jr., E. J. Cone, E. T. Moolchan, and M. A. Huestis. 2003. Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin. Chem. 49:121-132.
41. Schierenbeck, T., D. Riemann, M. Berger, and M. Hornyak. Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med. Rev. 12:381-389.
42. Smith, H. S. Opioid metabolism. Mayo Clinic Proc. 2009; 84:613-624.
43. Suzuki, T., and M. Misawa. 1997. Opioid receptor types and dependence. Nippon Yakurigaku Zasshi 109:165-74.
44. Staub, C.,M. Marset, A. Mino, and P. Mangin. 2001. Detection of acetylcodeine in urine as an indicator of illicit heroin use: Method validation and results of a pilot study. Clin. Chem. 47:301-307.
45. Ternes, T. A., P. Kreckel, and J. Mueller. 1999. Behaviour and occurrence of estrogens in municipal sewage treatment plants-II. Aerobic Batch experiments with active sludge. Sci. Total Environ. 225:91-99.
46. Thorn, C. F., T. E. Klein, R. B. Altman. 2009. Codeine and morphine pathway. Pharmacogenet. Genomics 19:556-558.
47. Trafton, J. A., and Ramani, A. 2009. Methadone: a new old drug with promises and pitfalls. Current Pain Headache Rep. 13:24-30.
48. United Nations Office of Drug and Crime (UNODC) World Drug Report 2004. Volume 2. Statistics. http://www.unodc.org/pdf/WDR_2004/methodology.pdf.
49. United Nation Office of Drug and Crime (UNODC) 2009. World Drug Report; 2009. http://www.unodc.org/documents/wdr/WDR_2009/WDR2009_eng_web.pdf.
50. Verstraete, A. G. 2004. Detection times of drugs of abuse in blood, urine, and oral fluid. Drug Monit. 26:200-205.
51. Williams, N., D. H. Clouet, A. L. Misra, and S. Mulè. 1977. Cocaine and metabolites: relationship between pharmacological activity and inhibitory action on dopamine uptake into striatal synaptosomes. Progr. Neuro-Psycopharmacol. 1:265-269.
52. Wood, R. W., J. Shojaie, C. Ping Fang, J. F. Graefe. 1995. Methylecgonidine coats the crack particle. Pharmacol. Biochem. Behav. 53:57-66.
53. Zuccato E., C. Chiabrando, S. Castiglioni, R. Bagnati, R. Fanelli. 2008. Estimating community drug abuse by wastewater analysis. Environ. Health Perspect. 116:1027-1032.